<DOC>
	<DOCNO>NCT02302443</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacokinetics ( PK ) ad pharmacodynamics ( PD ) HM12470 single injection T1DM T2DM patient .</brief_summary>
	<brief_title>A First-in-human Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics HM12470</brief_title>
	<detailed_description>This study design evaluate safety , tolerability , PK PD HM12470 single administration subject T1DM T2DM . In cohort study , safety , tolerability , PK PD HM12470 compare commercially available insulin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Inclusion Criteria T1DM : T2DM 12 monthM Age ≥18 ≤70 year Body mass index 18.0 35.0 kg/m2 inclusive . Considered generally healthy upon completion medical history , physical examination biochemical investigation judge Investigator . Females must nonpregnant nonlactating , either surgically sterile ( e.g. , tubal occlusion , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) postmenopausal &gt; 12 month . Males must surgically sterile , abstinent engage sexual relation childbearing potential , subject must use acceptable contraceptive method period 60 day last dose Study Drug . Signed date informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) . Inclusion Criteria T2DM : T1DM 12 monthM Age ≥18 ≤70 year Body mass index 18.0 30.0 kg/m2 inclusive . Considered generally healthy upon completion medical history , physical examination biochemical investigation judge Investigator . Females must nonpregnant nonlactating , either surgically sterile ( e.g. , tubal occlusion , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) postmenopausal &gt; 12 month . Males must surgically sterile , abstinent engage sexual relation childbearing potential , subject must use acceptable contraceptive method period 60 day last dose Study Drug . Signed date informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) . Exclusion Criteria A subject proliferative retinopathy maculopathy , severe gastroparesis , and/or severe neuropathy , particular autonomic neuropathy , judge Investigator Recurrent major hypoglycemia hypoglycemic unawareness recent ketoacidosis pregnant lactate woman participation investigational study within 30 day prior dose Clinically significant abnormal ECG screening , judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>